EMP2P1: A Promising Drug Target for Neurological and Developmental Disorders

Target Name: EMP2P1

NCBI ID: G391359

EMP2P1

Other Name(s): EMP2 pseudogene 1 | Epithelial membrane protein 2 pseudogene | LOC391359

EMP2P1: A Promising Drug Target for Neurological and Developmental Disorders

EMP2P1, also known as EMP2P1 gene or EMP2P1 protein, is a gene that encodes a protein known as EMP2P1. EMP2P1 is a key regulator of the microtubule network, which is a protein structure that plays a crucial role in the movement of cells and organelles within the body. Mutations in the EMP2P1 gene have been linked to a variety of neurological and developmental disorders, including those characterized by microtubule dysfunction. As a result, EMP2P1 has emerged as a promising drug target and potential biomarker for a variety of diseases.

The EMP2P1 gene is located on chromosome 6 and encodes a protein that is composed of 21 kDa. The protein is made up of two distinct subunits, A and B, which are held together by a disulfide bond. The A subunit contains the catalytic domain, which is responsible for the protein's unique catalytic activity. The B subunit contains a nucleotide-binding domain and a carboxy-terminal domain.

EMP2P1 functions as a critical regulator of the microtubule network. Microtubules are a protein structure that organizes the cytoskeleton and plays a central role in the movement of cells and organelles. They are composed of a series of double-wrapped tubules, each of which is composed of a series of microtubule filaments. These filaments are held in place by interactions with a variety of proteins, including EMP2P1.

EMP2P1 is responsible for the regulation of microtubule dynamics and stability. It does this by interacting with a variety of different proteins, including microtubule-associated proteins (MAPs) and other cytoskeleton components. These interactions help to maintain the stability and integrity of the microtubule network, and are critical for the proper functioning of the cell.

EMP2P1 has been implicated in a variety of neurological and developmental disorders. Mutations in the EMP2P1 gene have been linked to a range of disorders, including those characterized by microtubule dysfunction. For example, studies have suggested that mutations in the EMP2P1 gene may be responsible for the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential role in neurological disorders, EMP2P1 has also been shown to be involved in the development of a variety of other diseases. For example, studies have suggested that EMP2P1 mutations may be responsible for the development of cancer, and that these mutations may be particularly common in tissues that are highly dependent on the microtubule network, such as muscle and heart cells.

As a result of its involvement in a variety of biological processes, EMP2P1 has emerged as a promising drug target and potential biomarker for a variety of diseases. For example, studies have suggested that inhibiting the activity of EMP2P1 may be an effective way to treat a variety of neurological and developmental disorders, including those characterized by microtubule dysfunction. In addition, EMP2P1 has also been shown to be involved in the regulation of the growth and development of a variety of organisms, making it an attractive candidate for use as a drug or biomarker in a variety of fields, including biotechnology and medicine.

In conclusion, EMP2P1 is a gene that encodes a protein that is involved in the regulation of the microtubule network. Mutations in the EMP2P1 gene have been linked to a variety of neurological and developmental disorders, and as a result, EMP2P1 has emerged as a promising drug target and potential biomarker for a variety of diseases. Further research is needed to fully understand the role of EMP2P1 in

Protein Name: EMP2 Pseudogene 1

The "EMP2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMP2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets